NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, WHETHER DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, BELARUS OR ANY OTHER JURISDICTION WHERE SUCH DISTRIBUTION FURTHER REQUIRES PROSPECTUS, REGISTRATION, OR OTHER ACTIONS OTHER THAN THOSE UNDER SWEDISH LAW, ARE PROHIBITED, OR OTHERWISE CONTRARY TO APPLICABLE RULES IN SUCH JURISDICTION OR CANNOT TAKE PLACE WITHOUT APPLICATION OF EXCEPTIONS FROM SUCH ACTION. SEE THE "IMPORTANT INFORMATION" SECTION AT THE END OF THIS PRESS RELEASE.
Lipidor AB (publ) (the "Company" or "Lipidor") has completed the rights issue of units resolved by the Company's Board of Directors on 10 April 2024 and approved by the Extraordinary General Meeting on 21 May 2024 (the "Rights Issue"). The Board of Directors has today, based on the authorization granted by the Annual General Meeting held on 5 June 2024, in accordance with the underwriting agreements entered into and previously communicated, resolved on a directed issue of shares to the underwriters in the Rights Issue who have chosen to receive underwriting compensation in the form of newly issued shares in the Company (the "Compensation Issue"). The subscription price in the Compensation Issue is, through negotiations with the underwriters at arm’s length, set at SEK 0.05 per share, which corresponds to the subscription price per share in the Rights Issue, and payment is made by set-off of the underwriters' claims.
In connection with the Rights Issue, a number of external investors and existing shareholders provided underwriting undertakings. The Rights Issue was comprised to approximately 34 percent of bottom underwriting undertakings, approximately 9 percent of intermediate underwriting undertakings and approximately 8 percent of top underwriting undertakings. For the underwriting undertakings, underwriting compensation is paid, whereby compensation for top underwriters is set to 22 percent of the underwritten amount in the form of newly issued shares in the Company, compensation for intermediate underwriting undertakings is set to 20 percent of the underwritten amount in cash or 22 percent of the underwritten amount in the form of newly issued shares in the Company and compensation for bottom underwriting undertakings is set to 15 percent of the underwritten amount in cash or 17 percent of the underwritten amount in the form of newly issued shares in the Company.
A number of underwriters have chosen to receive their underwriting compensation in the form of newly issued shares in the Company. Therefore, the Board of Directors has, based on the authorization granted by the Annual General Meeting held on 5 June 2024, today resolved on the Compensation Issue, which comprises a total of 25,233,000 new shares. The underwriters who have not chosen to receive underwriting compensation in the form of newly issued shares will instead receive a cash amount for their respective underwriting undertakings. The cash part of the underwriting compensation amounts to approximately SEK 3.78 million.
The reason for the deviation from the shareholders' pre-emption rights in the Compensation Issue is to fulfil the Company's contractual obligation towards the underwriters. The Board of Directors also believes that it is to the benefit of the Company's financial position to take advantage of the opportunity to pay the underwriting compensation in the form of shares instead of through cash payment.
Payment in the Compensation Issue is made by set-off of each underwriter’s claim for underwriting compensation. The subscription price has been set at SEK 0.05 per share through negotiations at arm’s length with the underwriters. The subscription price corresponds to the subscription price per share in the Rights Issue. In light of this, the Board of Directors assesses that the subscription price is in line with market conditions. A total of SEK 1,261,650 is set-off in the Compensation Issue to the underwriters Aurena Laboratories Holding AB, Stefan Lundgren, Dennis Pedersen and Molly Baxi Thakkar. All shares in the Compensation Issue have been subscribed for and allotted.
Share capital and number of shares
Through the Compensation Issue, the number of shares in Lipidor will increase by 25,233,000 shares, from 788,170,675 shares to 813,403,675 shares, and the share capital will increase by SEK 50,466.00, from SEK 1,576,341.35 to SEK 1,626,807.35, corresponding to a dilution effect of approximately 3.1 percent.
LIPIDOR AB 
